Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada
Lauren Curry(BC Cancer Agency), Maryam Soleimani(BC Cancer Agency), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Frédéric Pouliot(Université Laval), Bimal Bhindi, Georg A. Bjarnason(Sunnybrook Health Science Centre), Vincent Castonguay(Centre hospitalier universitaire de Québec), Daniel Yick Chin Heng(University of Calgary), Rodney Breau(Ottawa Hospital), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Naveen S. Basappa(University of Alberta), Sunita Ghosh(University of Alberta), Dominick Bosse(University of Ottawa), Antonio Finelli(University Health Network), Erica Arenovich(Queen Elizabeth II Health Sciences Centre), Nazanin Fallah-Rad(University Health Network), Jeffrey Graham(University of Manitoba), Christian K. Kollmannsberger(BC Cancer Agency), Simon Tanguay(McGill University Health Centre)
Cited by 0
Related Papers
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
|Nature Communications|2019|225